Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Subscribe To Our Newsletter & Stay Updated
